Regeneration of a Functional Pulmonary Vascular Bed
AssigneeThe General Hospital Corporation
InventorsXi Ren, Harald C. Ott
Life of this patent
Estimating the term…
Abstract
A method for vascular regeneration comprises delivering endothelial cells to a lung scaffold, delivering perivascular cells to the lung scaffold, and providing a multiphase culture program to the scaffold. The multiphase culture program comprises a first phase including delivering an angiogenic medium, e.g., having 40-100 ng/ml of pro-angiogenic factors, and a second phase including delivering a stabilization medium, e.g., having 0.5-2% of serum and 1-20 ng/ml of angiogenic factors.
Claims7
-7. (canceled)
A method for differentiating endothelial and perivascular cells from human induced pluripotent stem cells (hiPSCs) comprising:
- (a) culturing the hiPSCs in the presence of at least one GSK3 inhibitor;
- (b) culturing the hiPSCs in the presence of a complete differentiating medium;
- (c) culturing the hiPSCs with the differentiating medium supplemented with a TGF-β1 inhibitor;
- and
- (d) separating hiPSC-derived perivascular progenitor cells (hiPSC-PPCs) and hiPSC-derived endothelial cells (hiPSC-ECs).
An airway organ bioreactor apparatus for vascular regeneration, comprising:
- a lung chamber;
- at least one ingress line communicably coupled to the lung chamber and configured for delivering endothelial cells to a lung scaffold and delivering perivascular cells to the lung scaffold;
- and
- a control module coupled to a pump, the control module configured to cause administration of a multiphase culture program to the lung scaffold, the multiphase culture program comprising:
- in a first phase, delivering an angiogenic medium having 40-100 ng/ml of pro-angiogenic factors, and
- in a second phase delivering a stabilization medium having 0.5-2% of serum and 1-20 ng/ml of angiogenic factors.
Dependencies are inferred from the claim text.